A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.

Trial Details

NCT ID
NCT07474727
Phase
PHASE2
Sponsor
Multitude Therapeutics Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • AMT-676
  • 5-FU
  • Leucovorin
  • Bevacizumab
  • Cetuximab
  • Irinotecan
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Nanning, Gaungxi, China|22.81667,108.31667
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Harbin, Heilongjiang, China|45.75,126.65

Key Eligibility Criteria

  • Patients must be willing and able to sign the ICF, and to adhere to the study visit schedule and other protocol requirements
  • Patients with pathologically confirmed, unresectable advanced colorectal adenocarcinoma
  • Patients must have at least one measurable lesion as per RECIST version 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →